BioSpace News Archive

Centessa Pharmaceuticals plc, announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension of AP-0101, a Phase 2a study of SerpinPC for the treatment of hemophilia, has been accepted for oral presentation at the 64th American Society of Hematology Annual Meeting, to be held in New Orleans, LA, from December 10 - 13, 2022.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it will present updated data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma, in a poster presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022 in New Orleans, LA.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces the expansion of its partnership with Pixee Medical through the commercialization of its combined surgical solution in the United States.

Robert Yu, CEO of Yuyu Pharma, has been attending biopharmaceutical conferences held in Germany, BIO-Europe and CPHI.

Arcellx, Inc. (NASDAQ: ACLX) today announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022, in New Orleans, Louisiana.

Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, Louisiana, and virtually.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced it has engaged Theradex Oncology, a leading clinical research organization (“CRO”), to help prepare for its upcoming clinical study of Ropidoxuridine.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that preclinical data from its P-FVIII-101 program, partnered with Takeda, has been selected for an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, being held in New Orleans and virtually December 10–13, 2022.

Poseida Therapeutics, Inc. announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.